Charles River Laboratories International (NYSE:CRL) Cut to “Hold” at StockNews.com

Charles River Laboratories International (NYSE:CRL) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the company. Evercore ISI increased their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. boosted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. UBS Group boosted their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Finally, Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.27.

Charles River Laboratories International Trading Down 0.2 %

NYSE CRL opened at $217.22 on Friday. Charles River Laboratories International has a one year low of $161.65 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The firm has a market cap of $11.19 billion, a P/E ratio of 25.56, a P/E/G ratio of 2.07 and a beta of 1.44. The stock’s 50-day moving average is $242.16 and its 200-day moving average is $229.04.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Sell-side analysts anticipate that Charles River Laboratories International will post 11 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 1,304 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Czech National Bank grew its holdings in shares of Charles River Laboratories International by 0.5% during the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock valued at $2,445,000 after purchasing an additional 41 shares during the last quarter. Cardinal Capital Management lifted its stake in shares of Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 8,450 shares of the medical research company’s stock valued at $1,998,000 after acquiring an additional 47 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Charles River Laboratories International by 21.5% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 58 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Charles River Laboratories International by 5.7% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock worth $266,000 after acquiring an additional 61 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC increased its holdings in Charles River Laboratories International by 1.4% in the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock worth $1,196,000 after purchasing an additional 62 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).